Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will announce topline results from the BroADen Phase 1b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis, on Monday, December 8, 2025.
A press release will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. A replay and presentation will be available after the event. Investors can register via the company website at www.kymeratx.com under News and Events.
Positive
- None.
Negative
- None.
Market Reaction 15 min delay 10 Alerts
Following this news, KYMR has gained 6.42%, reflecting a notable positive market reaction. Our momentum scanner has triggered 10 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $70.90. This price movement has added approximately $289M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
KYMR gained 0.86% while peers were mixed: MLTX +12.58%, SRRK +5.44%, APLS +3.94%, CRNX +1.37%, ZLAB -0.50%. No coherent sector move is evident.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Clinical trial start | Positive | +0.7% | First patient dosed in BROADEN2 Phase 2b KT-621 AD trial. |
| Nov 24 | Investor conferences | Neutral | -0.7% | Participation in multiple December investor fireside chats. |
| Nov 04 | Earnings and pipeline | Positive | +0.3% | Q3 2025 results with strong cash and KT-621 clinical progress. |
| Nov 03 | Investor conferences | Neutral | -3.4% | Expanded November conference schedule and webcast availability. |
| Oct 28 | Earnings date | Neutral | +1.8% | Announcement of Q3 2025 earnings release date and call details. |
News about clinical and corporate events has generally seen modest, directionally aligned price reactions, with one notable downside move on a conferences update.
Over the last few months, Kymera has reported multiple developments supporting KT-621 and its broader pipeline. On Oct 28, it scheduled Q3 2025 results, followed by actual earnings on Nov 4 showing $978.7M cash and ongoing KT-621 progress. Subsequent conference participation and the BROADEN2 Phase 2b dosing start on Nov 25 saw small price moves. Today’s announcement sets a specific Dec 8, 2025 catalyst for BroADen Phase 1b data, following previously telegraphed December timing.
Market Pulse Summary
The stock is up +6.4% following this news. A strong positive reaction aligns with the stock’s existing uptrend, trading near its $68.80 52-week high and above the $43.82 200-day MA. The company previously flagged December timing for BroADen Phase 1b data, so this firm date may have amplified enthusiasm. However, past news events produced relatively modest moves, and significant volatility around clinical readouts could reverse if results fail to meet investor expectations.
Key Terms
phase 1b medical
webcast technical
AI-generated analysis. Not financial advice.
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025
WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase 1b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, December 8, 2025. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.
To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be available following the event.
About KT-621
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. In the Phase 1 clinical study in healthy volunteers, KT-621 demonstrated complete STAT6 degradation in blood and skin following low daily oral doses, reductions of multiple disease relevant Type 2 biomarkers, and a safety profile undifferentiated from placebo. KT-621, the first STAT6-directed drug to enter clinical evaluation, has the potential to transform treatment paradigms for more than 130 million patients around the world, including children and adults, suffering from Type 2 diseases such as atopic dermatitis (AD), asthma, bullous pemphigoid (BP), chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), chronic spontaneous urticaria (CSU), and prurigo nodularis (PN), among others.
The Company’s KT-621 BROADEN2 Phase 2b trial in moderate to severe AD patients is ongoing, and patient dosing has commenced. Data is expected to be reported by mid-2027. The BREADTH Phase 2b trial in asthma is planned to start in the first quarter of 2026. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Type 2 dermatology, gastroenterology and respiratory indications.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
When will Kymera (NASDAQ: KYMR) release BroADen Phase 1b KT-621 results?
What time is the Kymera KT-621 webcast and how can I join on December 8, 2025?
What is KT-621 and which condition was it tested for in BroADen Phase 1b?
Will Kymera provide a replay or presentation from the December 8, 2025 event?
Where can investors find regulatory or follow-up details after Kymera's KT-621 announcement?
